NASDAQ:HJLI - Hancock Jaffe Laboratories Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.98 -0.19 (-5.99 %) (As of 07/16/2018 04:00 PM ET)Previous Close$3.17Today's Range$2.79 - $3.3052-Week Range$2.79 - $5.64Volume68,482 shsAverage Volume216,138 shsMarket Capitalization$36.48 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileHeadlinesOptions ChainSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA. Receive HJLI News and Ratings via Email Sign-up to receive the latest news and ratings for HJLI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical SymbolNASDAQ:HJLI CUSIPN/A Webwww.hancockjaffe.com Phone949-261-2900 Debt Debt-to-Equity Ratio-0.29 Current Ratio0.03 Quick Ratio0.03 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees12 Outstanding Shares11,510,000Market Cap$36.48 Hancock Jaffe Laboratories (NASDAQ:HJLI) Frequently Asked Questions What is Hancock Jaffe Laboratories' stock symbol? Hancock Jaffe Laboratories trades on the NASDAQ under the ticker symbol "HJLI." What is the consensus analysts' recommendation for Hancock Jaffe Laboratories? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hancock Jaffe Laboratories in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Hancock Jaffe Laboratories' key competitors? Some companies that are related to Hancock Jaffe Laboratories include Motus GI (MOTS), Sensus Healthcare (SRTS), Invuity (IVTY), Restoration Robotics (HAIR), Alphatec (ATEC), Invo Bioscience (IVOB), Neovasc (NVCN), Arch Therapeutics (ARTH), Spectral Medical (EDTXF), CAS Medical Systems (CASM), SANUWAVE Health, Inc. Common Stock (SNWV), iCAD (ICAD), Repro-Med Systems (REPR), Nephros (NEPH) and Valeritas (VLRX). Who are Hancock Jaffe Laboratories' key executives? Hancock Jaffe Laboratories' management team includes the folowing people: Ms. Susan Montoya, Sr. VP of Operations, Regulatory Affairs & Quality Assurance (Age 67)Dr. Benedict Broennimann M.D., Chief Medical Officer, OUS (Age 61)Dr. Marc H. Glickman, Sr. VP & Chief Medical Officer (Age 69)Mr. Robert A. Berman, CEO & Director (Age 55)Mr. Warren Hancock, Co-founder When did Hancock Jaffe Laboratories IPO? (HJLI) raised $8 million in an initial public offering (IPO) on Thursday, May 31st 2018. The company issued 1,500,000 shares at $5.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO and ViewTrade Securities was co-manager. When did the company's quiet period expire? Hancock Jaffe Laboratories' quiet period expired on Tuesday, July 10th. Hancock Jaffe Laboratories had issued 1,500,000 shares in its public offering on May 31st. The total size of the offering was $7,500,000 based on an initial share price of $5.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. Has Hancock Jaffe Laboratories been receiving favorable news coverage? Media stories about HJLI stock have trended somewhat negative on Monday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hancock Jaffe Laboratories earned a coverage optimism score of 0.00 on Accern's scale. They also gave news headlines about the company an impact score of 44.27 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. How do I buy shares of Hancock Jaffe Laboratories? Shares of HJLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Hancock Jaffe Laboratories' stock price today? One share of HJLI stock can currently be purchased for approximately $2.98. How big of a company is Hancock Jaffe Laboratories? Hancock Jaffe Laboratories has a market capitalization of $36.48 million. Hancock Jaffe Laboratories employs 12 workers across the globe. How can I contact Hancock Jaffe Laboratories? Hancock Jaffe Laboratories' mailing address is 70 DOPPLER, IRVINE CA, 92618. The company can be reached via phone at 949-261-2900. MarketBeat Community Rating for Hancock Jaffe Laboratories (NASDAQ HJLI)Community Ranking: 1.8 out of 5 ()Outperform Votes: 4 (Vote Outperform)Underperform Votes: 7 (Vote Underperform)Total Votes: 11MarketBeat's community ratings are surveys of what our community members think about Hancock Jaffe Laboratories and other stocks. Vote "Outperform" if you believe HJLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HJLI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?